Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Tsumura & Co ( (JP:4540) ) just unveiled an update.
Tsumura & Co. has revised its Medium-Term Management Plan for FY2025-FY2027, increasing its operating profit and ROE targets due to better-than-expected business performance. The upward revision is driven by the consolidation of Shanghai Hongqiao Traditional Chinese Drug Pieces Co., Ltd., cost reductions, and effective expense management, positioning the company for improved financial outcomes despite inflationary pressures.
The most recent analyst rating on (JP:4540) stock is a Hold with a Yen3870.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.
More about Tsumura & Co
Tsumura & Co. operates in the pharmaceutical industry, focusing on traditional Chinese medicine. The company is known for its herbal medicine products and has a significant market presence in Japan and China.
YTD Price Performance: -22.02%
Average Trading Volume: 390,846
Technical Sentiment Signal: Hold
Current Market Cap: Yen271.5B
For detailed information about 4540 stock, go to TipRanks’ Stock Analysis page.